While Sandoz has emerged as the front-runner to get a generic version of GlaxoSmithKline’s respiratory blockbuster Advair to the US market, rival Hikma has not given up despite a major setback.

UK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for approval of its generic of GlaxoSmithKline’s blockbuster respiratory drug Advair. Hikma has been ...

The US Food and Drug Administration approved Hikma's Abbreviated New Drug Application (ANDA) for generic Advair Diskus in December 2020. However, the company has since submitted an amendment to ...

(Alliance News) - Hikma Pharmaceuticals PLC announced on Tuesday it has completed its acquisition of the US finished dosage form business. Denmark-bas... (Sharecast News) - London stocks ended ...

Hikma’s generic version of Xyrem only reached the market last year, following a 2017 settlement that the plaintiffs allege was an unlawful “reverse payment agreement” designed to delay ...

Hikma is offering clindamycin in 5% dextrose injection, in 300mg/50ml, 600mg/50ml and 900mg/50ml doses. The product is available in a vial. Clindamycin in 5% dextrose injection is indicated for ...

The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in ...

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience. To access our Live RNS you must confirm you are a private ...

Aug 27 (Reuters) - Drug companies Jazz (JAZZ.O), opens new tab and Hikma (HIK.L), opens new tab must face claims that they schemed to delay a generic version of Jazz’s blockbuster narcolepsy ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) and Hikma Pharmaceuticals Plc (OTC:HKMPF) (OTC:HKMPY) are set to face allegations that ...